Publication Name	World Journal of Gastroenterology
Manuscript ID	111435
Country	Peru

Received	2025-06-30 09:16
Peer-Review Started	2025-06-30 09:16
To Make the First Decision
Return for Revision	2025-07-14 09:55
Revised	2025-07-24 02:26
Second Decision	2025-08-25 03:47
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-08-25 06:28
Articles in Press	2025-08-25 06:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-09-05 00:33
Publish the Manuscript Online	2025-09-25 03:33

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review
Manuscript Source	Invited Manuscript
All Author List	Marcio J Concepción-Zavaleta, Jenyfer M Fuentes-Mendoza, Jhean G Gonzáles-Yovera, Gemma Y Ruvalcaba-Barbosa, Leonardo D Cura-Rodríguez, Josué S González-Rodríguez, Luis A Concepción-Urteaga, Aranza I Pérez-Reyes, Juan Eduardo Quiroz-Aldave and José Paz-Ibarra
ORCID	Author(s) ORCID Number Marcio J Concepción-Zavaleta http://orcid.org/0000-0001-9719-1875 Jenyfer M Fuentes-Mendoza http://orcid.org/0000-0002-4682-3999 Jhean G Gonzáles-Yovera http://orcid.org/0000-0002-5809-3006 Gemma Y Ruvalcaba-Barbosa http://orcid.org/0009-0003-3423-2942 Leonardo D Cura-Rodríguez http://orcid.org/0009-0005-8324-2391 Josué S González-Rodríguez http://orcid.org/0009-0002-9372-7315 Luis A Concepción-Urteaga http://orcid.org/0000-0003-0462-3101 Aranza I Pérez-Reyes http://orcid.org/0009-0003-1560-3859 Juan Eduardo Quiroz-Aldave http://orcid.org/0000-0001-8286-095X José Paz-Ibarra http://orcid.org/0000-0002-2851-3727
Funding Agency and Grant Number
Corresponding Author	Marcio J Concepción-Zavaleta, Grupo de Investigación Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, 19 Panamericana Sur Km, Villa El Salvador, Lima 15067, Peru. mconcepcion@cientifica.edu.pe
Key Words	Obesity; Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Glucagon-like peptide-1 receptor agonists; Tirzepatide; Retatrutide; Anti-obesity medications
Core Tip	Obesity is a leading modifiable risk factor for chronic liver disease, particularly metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. Glucagon-like peptide-1 receptor agonists and emerging dual and triple incretin agonists offer promising metabolic and hepatic benefits. However, their use in advanced liver disease raises concerns due to altered pharmacokinetics and limited safety data. This review synthesizes current evidence on the efficacy and safety of anti-obesity medications in individuals with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and underscores the need for personalized treatment strategies and robust clinical trials.
Publish Date	2025-09-25 03:33
Citation	<p>Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, Concepción-Urteaga LA, Pérez-Reyes AI, Quiroz-Aldave JE, Paz-Ibarra J. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. <i>World J Gastroenterol</i> 2025; 31(37): 111435</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i37/111435.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i37.111435

Full Article (PDF)	WJG-31-111435-with-cover.pdf
Manuscript File	111435_Auto_Edited_032012.docx
Answering Reviewers	111435-answering-reviewers.pdf
Audio Core Tip	111435-audio.mp3
Conflict-of-Interest Disclosure Form	111435-conflict-of-interest-statement.pdf
Copyright License Agreement	111435-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	111435-non-native-speakers.pdf
Peer-review Report	111435-peer-reviews.pdf
Scientific Misconduct Check	111435-scientific-misconduct-check.png
Scientific Editor Work List	111435-scientific-editor-work-list.pdf
CrossCheck Report	111435-crosscheck-report.pdf